Search Results
Brian Huntly | ISAL 2019 | Epigenetic mechanisms as targets for AML therapy
How can genetic studies inform the treatment of AML?
What are mutational patterns, and do they affect outcomes of patients with acute myeloid leukemia?
Brian Huntly, University of Cambridge, HARMONY Partner
Biology of AML Developing from MDS vs. de Novo AML, and New Targets for Therapy
What is the clinical significance of co-mutational patterns in AML?
What is the impact of EZH2 mutations in AML?
How will targeted therapies be used in the future?
The molecular mechanisms of epigenetic therapies: LTRs and TINATs
Peter's story: stem cells and blood cancers
M Figueroa AML Epigenetics BTG2011
Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
